Living Well With Chronic Lymphocytic Leukemia: Education, Empowerment and Learning From Others | Houston, TX


Sunday, October 25th
MD Anderson Cancer Center
Houston, Texas


An audience of CLL patients and their caregivers joined us at a recent town meeting at The University of Texas MD Anderson Cancer Center to hear about emerging therapies in CLL, current treatment options and support resources.

We are also planning events in other cities. If you haven’t already, please sign up for email updates, so we can alert you when important and inspiring videos become available and when upcoming town meetings are scheduled.


Patient Folder





Understanding the Relationship Between Genetic Testing and Targeted Therapy

Giving a thorough description of FISH and CLL profiling, Drs. Michael Keating and Nicole Lamanna emphasize the need to get the right test done at the right time to obtain the best targeted therapy.



CLL Defined

Drs. Nicole Lamanna and Michael Keating, along with Andrew Schorr, get back to CLL basics, describing and defining the disease in easy-to-understand terms.


What Are the Symptoms of CLL and How Does It Progress?

What are the symptoms of CLL? When should treatment begin? CLL experts Dr. Zeev Estrov, Dr. Nicole Lamanna and Dr. Michael Keating weigh in.


Guest Presenters to Include:

Associate Clinical Professor of Medicine

Columbia University Medical Center

Professor of Medicine and Internist, Director of Hematopoiesis Research, Department of Leukemia

Patient Advocate


Host, Patient Power Co-Founder, CLL Patient and Advocate

Online Host, Patient Power Co-Founder, Caregiver and Patient Advocate


This town meeting was provided by CLL Global Research Foundation, which received support from AbbVie Inc., Genentech Inc., Gilead Sciences, Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc. and Teva Pharmaceuticals. It was produced by Patient Power in partnership with The University of Texas MD Anderson Cancer Center.





Join Our Community Register for Events Read Our Latest Blog

Page last updated on March 5, 2019